Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | CAD | P27708 | 1/20 | 0.39 |
| ▸ | RRM1 | P23921 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | OTC | P00480 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9342965 | 1.00 | DPP7 (0.45) | DPP7NOD1GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL6354171 | 0.98 | DPP7 (0.44) | DPP7NOD1GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL6354173 | 0.98 | DPP7 (0.44) | DPP7NOD1GNAI3GNAO1GNAI1 | |
| SCHEMBL93606 | 0.87 | DPP7 (0.42) | DPP7NOD1GNAI3GNAO1GNAI1 | |
| SCHEMBL9330200 | 0.87 | DPP7 (0.42) | DPP7NOD1GNAI3GNAO1GNAI1 | |
| SCHEMBL93607 | 0.87 | DPP7 (0.42) | DPP7NOD1GNAI3GNAO1GNAI1 | |
| SCHEMBL8580173 | 0.86 | DPP7 (0.43) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL11787815 | 0.86 | DPP7 (0.43) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| Hydrochloric Acid SCHEMBL22411245 | 0.85 | DPP7 (0.41) | DPP7NOD1GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL569999 | 0.85 | DPP7 (0.41) | DPP7NOD1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205181-A1 | ANANDAMIDE CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | CZAP RESEARCH AND DEVELOPMENT, LLC | 2025-06-26 | — | — | US | claimed |
| EP-4380556-A1 | ANANDAMIDE CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | Czap Research And Development, LLC (US) | 2024-06-12 | — | — | EP | claimed |
| WO-2023012552-A1 | ANANDAMIDE CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | CZAP RESEARCH AND DEVELOPMENT, LLC (US) | 2023-02-09 | — | — | WO | claimed |
| EP-2819635-A1 | COMBINATION PRODUCT FOR TREATING EXCESS WEIGHT AND/OR FOR IMPROVING THE FIGURE | Institut National De La Recherche Agronomique (INRA) (FR) | 2015-01-07 | — | — | EP | claimed |
| WO-2013128137-A1 | COMBINATION PRODUCT FOR TREATING EXCESS WEIGHT AND/OR FOR IMPROVING THE FIGURE | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE - INRA (FR) | 2013-09-06 | — | — | WO | claimed |
| CN-1091952-A | Cosmetic composition | UNILEVER NV (NL) | 1994-09-14 | — | — | CN | claimed |
| US-20250205181-A1 | ANANDAMIDE CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | CZAP RESEARCH AND DEVELOPMENT, LLC | 2025-06-26 | — | — | US | disclosed |
| EP-4380556-A1 | ANANDAMIDE CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | Czap Research And Development, LLC (US) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023012552-A1 | ANANDAMIDE CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | CZAP RESEARCH AND DEVELOPMENT, LLC (US) | 2023-02-09 | — | — | WO | disclosed |
| CN-109311792-B | Phenylether derivative, preparation method thereof, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-10-21 | — | — | CN | disclosed |
| WO-2020231906-A1 | SPORTS AND NUTRITIONAL SUPPLEMENT FORMULATIONS | BGS HOLDINGS LLC (US) | 2020-11-19 | — | — | WO | disclosed |
| US-20190314312-A1 | COMBINATION THERAPY TO INCREASE ENDOGENOUS NITRIC OXIDE (NO) SYNTHESIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2019-10-17 | — | — | US | disclosed |
| EP-3481386-A1 | COMBINATION THERAPY TO INCREASE ENDOGENOUS NITRIC OXIDE (NO) SYNTHESIS | Yeda Research and Development Co., Ltd. (IL) | 2019-05-15 | — | — | EP | disclosed |
| WO-2018011806-A1 | COMBINATION THERAPY TO INCREASE ENDOGENOUS NITRIC OXIDE (NO) SYNTHESIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-01-18 | — | — | WO | disclosed |
| EP-2819635-A1 | COMBINATION PRODUCT FOR TREATING EXCESS WEIGHT AND/OR FOR IMPROVING THE FIGURE | Institut National De La Recherche Agronomique (INRA) (FR) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013128137-A1 | COMBINATION PRODUCT FOR TREATING EXCESS WEIGHT AND/OR FOR IMPROVING THE FIGURE | INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE - INRA (FR) | 2013-09-06 | — | — | WO | disclosed |
| US-20010056068-A1 | METHOD OF TREATMENT AND PREVENTION OF NITRIC OXIDE DEFICIENCY-RELATED DISORDERS WITH CITRULLINE AND CITRULLINE DERIVATIVES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2001-12-27 | — | — | US | disclosed |
| CN-1091952-A | Cosmetic composition | UNILEVER NV (NL) | 1994-09-14 | — | — | CN | disclosed |
| US-5304470-A | Process for the enzymatic preparation of protected and unprotected di- and oligopeptides in aqueous solutions | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 1994-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314312-A1 | COMBINATION THERAPY TO INCREASE ENDOGENOUS NITRIC OXIDE (NO) SYNTHESIS | NOS2, NOS1, NOS3 | DPP7 2834/4885NOD1 342/4885GNAI3 2005/4885 |
| US-20250205181-A1 | ANANDAMIDE CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | AADAC, SI, CNDP2 | DPP7 3110/4885NOD1 402/4885GNAI3 3457/4885 |
| US-20010056068-A1 | METHOD OF TREATMENT AND PREVENTION OF NITRIC OXIDE DEFICIENCY-RELATED DISORDERS WITH CITRULLINE AND CITRULLINE DERIVATIVES | PGF, NOS2, NOS1 | DPP7 2118/4885NOD1 4526/4885GNAI3 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.